<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="METABOLIZED ANTICONVULSANTS" code="N03A-002" /></DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations and of the effectiveness of the anticonvulsant

.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PROTON PUMP INHIBITORS" code="A02BC-001" /></DRUG2>
<DESCRIPTION>Risk of ineffectiveness of the treatment by the proton pump inhibitor due to decrease of its metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="VITAMIN K ANTAGONISTS" code="B01AA-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the vitamin K antagonist, by reason of its enzymatic inducer effect, with risk of reduction of effectiveness, even complete loss of the effect, which could have possibly serious consequences (thrombolitic event)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>In case of an accidental use of the two substances together, do not stop the St Johns Wort suddenly, but test the INR before and then after the St Johns Wort is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="BEDAQUILINE" rxcui="1364504">
<ATC code="J04AK05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of bedaquiline due to increase of its metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CARBAMAZEPINE" rxcui="2002">
<ATC code="N03AF01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations and of the effectiveness of the carbamazepine</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="COBICISTAT" rxcui="1306284">
<ATC code="V03AX03" />
<ATC code="J05AR09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the cobicistat due to increase of its metabolism by the inducer</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CYPROTERONE" rxcui="3014">
<ATC code="G03HA01" />
<ATC code="G03HB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the cyproterone, due to increase of its hepatic metabolism by the St Johns Wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DACLATASVIR" rxcui="1606218">
<ATC code="J05AX14" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of significant decrease of the plasma concentrations of daclatasvir due to increase of its hepatic metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DASABUVIR" rxcui="1597381">
<ATC code="J05AX16" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of the dasabuvir by the St Johns wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIGOXIN" rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the digoxinemia, because of the enzymatic inducer effect of the St Johns Wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (acute decompensated heart failure).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>In the case of the two substances being taken by accident, do not stop the St Johns Wort abruptly but test the plasma concentrations (or the effectiveness) of the digoxin before and then after the St Johns Wort is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DOLUTEGRAVIR" rxcui="1433868">
<ATC code="J05AX12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of dolutegravir due to increase of its metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large decrease of the concentrations of dronedarone due to increase of its metabolism, without significant modification of the active metabolite</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ERIBULINE" rxcui="1045453">
<ATC code="L01XX41" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of eribuline by the St Johns wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="COMBINED ESTROGEN-PROGESTIN CONTRACEPTIVES" code="G03AB-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the hormonal contraceptive, because of the enzymatic inducer effect of the St Johns Wort, with risk of reduction of effectiveness, even complete loss of the effect which can have possibly serious consequences (pregnancy).</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="IDELALISIB" rxcui="1544460">
<ATC code="L01XX47" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of large decrease of the plasma concentrations of idelalisib due to increase of its hepatic metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IRREVERSIBLE MONOAMINE OXIDASE INHIBITORS (MAOI)" code="N06AF0" /></DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="REVERSIBLE MAOI-A, INCLUDING LINEZOLIDE AND METHYLENE BLUE" code="NO6AG-001" /></DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="IMMUNOSUPPRESSANTS" code="L04A" /></DRUG2>
<DESCRIPTION>Decrease of the blood concentrations of the immunosuppressant, because of the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which could have possibly serious consequences (rejection of a graft)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the protease inhibitor, due to the enzymatic inducer effect of the St Johns Wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (reduction of the antiretroviral effectiveness)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>In the case of the substances being taken together by accident, do not stop the St Johns Wort abruptly, but test the plasma concentrations (or the effectiveness) of the protease inhibitor before and then after the St Johns Wort is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="METABOLIZED TYROSINE-KINASE INHIBITORS " code="L01XE" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations and of the effectiveness of the tyrosine-kinase inhibitor, due to increase of its metabolism by the St Johns Wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)" code="N06AB" /></DRUG2>
<DESCRIPTION>Risk of appearance of a serotonin syndrome</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Regular clinical and biological monitoring, especially at the beginning of the administration of the substances together. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="IRINOTECAN" rxcui="51499">
<ATC code="L01XX19" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the active metabolite of the irinotecan, with risk of failure of the cytotoxic treatment</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ISAVUCONAZOLE" rxcui="1720882">
<ATC code="J02AC05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of isavuconazole due to increase of its hepatic metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of large decrease of the plasma concentrations of itraconazole, with risk of loss of effectiveness, due to increase of its hepatic metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="IVABRADINE" rxcui="77417">
<ATC code="C01EB17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effectiveness of the ivabradine due to increase of its metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LEDIPASVIR" rxcui="1591922">
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of large decrease of the plasma concentrations of the ledipasvir due to increase of its hepatic metabolidm by the St Johns wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LOMITAPIDE" rxcui="1364479">
<ATC code="C10AX12" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of the lomitapide</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="LURASIDONE" rxcui="1040028">
<ATC code="N05AE05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the lurasidone due to increase of its hepatic metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MACITENTAN" rxcui="1442132">
<ATC code="C02KX0" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of macitentan due to increase of its metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MARAVIROC" rxcui="620216">
<ATC code="J05AX09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of maraviroc that could lead to a loss of virological response</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="MIDAZOLAM" rxcui="6960">
<ATC code="N05CD08" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of midazolam by the St Johns wort</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NEVIRAPINE" rxcui="53654">
<ATC code="J05AG01" />
<ATC code="J05AR07" />
<ATC code="J05AR05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of significant decrease of the plasma concentrations of the nevirapine due to increase of its hepatic metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="NINTEDANIB" rxcui="1592737">
<ATC code="L01XE31" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the nintedanib due to decrease of its absorption by the St Johns Wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="OXYCODONE" rxcui="7804">
<ATC code="N02AA55" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the oxycodone due to increase of its metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Possible adjustment of the dosage of the oxycodone.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="PROGESTIN CONTRACEPTIVES" code="G03-001" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the hormonal contraceptive, because of the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (pregnancy)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PROPAFENONE" rxcui="8754">
<ATC code="C01BC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the propafenone due to increase of its hepatic metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG. If there is reason for it, adjustment of the dosage of the propafenone during the time the substances are administered together and after the St Johns wort is stopped. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="QUETIAPINE" rxcui="51272">
<ATC code="N05AH04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Very large decrease of the plasma concentrations of quetiapine due to increase of its hepatic metabolism by the inducer, with risk of ineffectiveness</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="REGORAFENIB" rxcui="1312397">
<ATC code="L01XE21" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of regorafenib due to increase of its metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="RILPIVIRINE" rxcui="1102270">
<ATC code="J05AG05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of rilpivirine due to increase of its hepatic metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SIMEPREVIR" rxcui="1482790">
<ATC code="J05AE14" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of simeprevir due to increase of its hepatic metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SIMVASTATIN" rxcui="36567">
<ATC code="C10AA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the effectiveness of the cholesterol lowering agent due to increase of its hepatic metabolism by the St Johns wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="SOFOSBUVIR" rxcui="">
<ATC code="J05AX15" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of sofobusvir due to decrease of its intestinal absorption by the St Johns wort</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TELAPREVIR" rxcui="1102261">
<ATC code="J05AE11" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of very large decrease of the concentrations of telaprevir</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TELITHROMYCIN" rxcui="274786">
<ATC code="J01FA15" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the telithromycin, with risk of failure of the antibiotic treatment, due to increase of the hepatic metabolism of the telithromycin by the St Johns wort</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THEOPHYLLINE (AND, BY EXTRAPOLATION, AMINOPHYLLINE)" code="R03DA" /></DRUG2>
<DESCRIPTION>Decrease of the plasma concentrations of the theophylline, because of the enzymatic inducer effect of the St Johns wort, with risk of reduction of effectiveness, even complete loss of the effect, which can have possibly serious consequences (onset of an obstructive pulmonary syndrome) </DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
<COMMENT>In case of accidental use of the substances together, do not stop the St Johns wort abruptly but test the plasma concentrations (or the effectiveness) of the medication taken with it before and then after stopping the St Johns wort. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of large decrease of the plasma concentrations of ticagrelor due to increase of its hepatic metabolism by the St Johns wort, with decrease of its therapeutic effect</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ULIPRISTAL" rxcui="1005921">
<ATC code="G03AD02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the effect of the ulipristal, due to increase of its hepatic metabolism by the inducer</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>Choose a therapeutic alternative that is little or not metabolized.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large reduction of the concentrations of verapamil, with risk of loss of its therapeutic effect</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VISMODEGIB" rxcui="1242987">
<ATC code="L01XX43" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of decrease of the plasma concentrations of vismodegib</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>356-ST-JOHNS-WORT.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ST JOHNS WORT" rxcui="258326">
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Large reduction of the concentrations of voriconazole, with risk of loss of its therapeutic effect</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
</INTERACTIONS>
